Related Experiment Videos
Perspectives on plasmid-based gene therapy: challenges for the product and the process
1Chemical Engineering Department, Villanova University, 318 White Hall, 800 Lancaster Ave, Villanova, PA 19085, USA. william.j.kelly@villanova.edu
Biotechnology and Applied Biochemistry
|April 4, 2003
Summary
Gene therapy clinical trials are advancing, with DNA plasmids emerging as a safer alternative to viral vectors. This work explores the manufacturing and expression challenges for plasmid-based gene therapies.
Area of Science:
- Biotechnology
- Molecular Biology
- Gene Therapy
Background:
- Gene therapy clinical trials commenced in the 1990s, with a majority currently in Phase I and II.
- Safety concerns with viral vectors have led to increased use of DNA plasmids in approximately 25% of ongoing trials.
Purpose of the Study:
- To highlight unique technical challenges in manufacturing plasmid-based gene therapy products.
- To discuss potential solutions for the expression of plasmid-based gene therapy products.
Main Methods:
- This perspective reviews current trends and challenges in gene therapy development.
- Focuses on the technical aspects of plasmid DNA production and delivery for therapeutic applications.
Main Results:
- Identifies key hurdles in the large-scale manufacturing of clinical-grade plasmid DNA.
- Discusses strategies for optimizing gene expression from plasmid vectors in target cells.
Conclusions:
- Addressing manufacturing and expression challenges is crucial for the successful clinical translation of plasmid-based gene therapies.
- Further innovation in production and delivery technologies will accelerate the development of these advanced therapies.